First-line pembrolizumab monotherapy met the primary end point of PFS in dMMR advanced/recurrent endometrial cancer.
|Videos|April 29, 2011
Dr. Karlan Describes AMG 386 Side Effects
Author(s)Beth Y. Karlan MD
Dr. Karlan Describes AMG 386 Side Effects Found in the Phase II Ovarian Cancer Trial
Advertisement
Beth Y. Karlan MD, a Director at Cedars-Sinai Women's Cancer Research Institute Describes AMG 386 Side Effects Found in the Phase II Ovarian Cancer Trial
Advertisement
Related to this article
In case you missed any, check out our recap of the episodes of OncLive On Air that aired in June 2026.
Advertisement
Advertisement
Trending on OncLive
1
FDA Grants Fast Track Designation to Pelareorep in Pretreated SCAC
2
PRAME-Directed Therapies Advance Melanoma Treatment Across Clinical Settings
3
META 10-19 Elicits High Complete Response Rate at Ultra-Low Doses in High-Risk R/R DLBCL
4
Dr Falchi on Critical Unmet Needs and Important Next Steps in DLBCL
5